| Q35487689 | A host susceptibility gene, DR1, facilitates influenza A virus replication by suppressing host innate immunity and enhancing viral RNA replication |
| Q42595471 | A proline-based neuraminidase inhibitor: DFT studies on the zwitterion conformation, stability and formation |
| Q28471710 | A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination |
| Q45414980 | An emerging avian influenza A virus H5N7 is a genetic reassortant of highly pathogenic genes. |
| Q35811472 | Anti-Influenza Activity of Betulinic Acid from Zizyphus jujuba on Influenza A/PR/8 Virus |
| Q58066873 | Anti-influenza therapy: the emerging challenge of resistance |
| Q38012651 | Antituberculosis drug research: a critical overview. |
| Q42981047 | Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses |
| Q24635330 | Antiviral drugs for viruses other than human immunodeficiency virus |
| Q30358735 | Antiviral management of seasonal and pandemic influenza. |
| Q30368782 | Antiviral medication use in a cohort of pregnant women during the 2009-2010 influenza pandemic. |
| Q33826335 | Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. |
| Q28469119 | Antiviral resistance and the control of pandemic influenza |
| Q30363640 | Antiviral treatment for the control of pandemic influenza: some logistical constraints |
| Q30377241 | Antivirals for the treatment and prevention of epidemic and pandemic influenza |
| Q42616940 | Assay to detect H5N1 oseltamivir resistance |
| Q30419211 | Assessing households' willingness to pay for an immediate pandemic influenza vaccination programme |
| Q40734518 | Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. |
| Q21142689 | Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases |
| Q30361041 | Avian influenza virus (H5N1): a threat to human health. |
| Q64901554 | Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. |
| Q35105705 | Biosynthetic gene cluster of cetoniacytone A, an unusual aminocyclitol from the endosymbiotic Bacterium Actinomyces sp. Lu 9419. |
| Q40997093 | Can treatment increase the epidemic size? |
| Q30394067 | Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses |
| Q42280448 | Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009-2011. |
| Q28484222 | Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats |
| Q30408112 | Combination chemotherapy for influenza |
| Q59350050 | Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection |
| Q42274102 | Combined administration of oseltamivir and hochu-ekki-to (TJ-41) dramatically decreases the viral load in lungs of senescence-accelerated mice during influenza virus infection |
| Q30421991 | Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir |
| Q30403144 | Computer-based de novo designs of tripeptides as novel neuraminidase inhibitors |
| Q30363190 | Continuing challenges in influenza. |
| Q45810645 | Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States |
| Q30445738 | Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. |
| Q30374227 | Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. |
| Q34015113 | Developing new antiviral agents for influenza treatment: what does the future hold? |
| Q97539807 | Development of A4 antibody for detection of neuraminidase I223R/H275Y-associated antiviral multidrug-resistant influenza virus |
| Q30394113 | Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan |
| Q28479036 | Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses |
| Q35758840 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus |
| Q40152886 | Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial |
| Q36785817 | Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice |
| Q28473051 | Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses |
| Q30403055 | Emergence of oseltamivir-resistant pandemic H1N1 in an immunocompetent child with severe status asthmaticus |
| Q42265723 | Emerging multiple reassortant H5N5 avian influenza viruses in ducks, China, 2008. |
| Q30385708 | Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. |
| Q33354941 | Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir |
| Q34339407 | Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses |
| Q30362700 | Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact. |
| Q43828480 | Evaluation of two Japanese regulatory actions using medical information databases: a 'Dear Doctor' letter to restrict oseltamivir use in teenagers, and label change caution against co-administration of omeprazole with clopidogrel |
| Q30401118 | Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage |
| Q30421871 | Evidence-based medicine and the governance of pandemic influenza |
| Q35056208 | Exploring naphthyl-carbohydrazides as inhibitors of influenza A viruses |
| Q35809685 | First introduction of highly pathogenic H5N1 avian influenza A viruses in wild and domestic birds in Denmark, Northern Europe |
| Q30425932 | Genetic Analysis of Avian Influenza Viruses: Cocirculation of Avian Influenza Viruses with Allele A and B Nonstructural Gene in Northern Pintail (Anas acuta) Ducks Wintering in Japan |
| Q44805348 | Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). |
| Q30363930 | Glycosidase inhibitors: a patent review (2008-2013). |
| Q30379409 | H1N1 2009 influenza virus infection during pregnancy in the USA. |
| Q30381621 | H1N1 Influenza in Pregnancy: What All Obstetric Care Providers Ought to Know. |
| Q30391963 | Highly Sensitive and Quantitative Detection of the H274Y Oseltamivir Resistance Mutation in Seasonal A/H1N1 Influenza Virus |
| Q33855399 | Identification of Novel and Efficacious Chemical Compounds that Disturb Influenza A Virus Entry in vitro |
| Q45353103 | Identification of potential inhibitors of H5N1 influenza A virus neuraminidase by ligand-based virtual screening approach |
| Q50072908 | Impact of data transparency: Scientific publications |
| Q35759115 | Importance of collection tube during clinical studies of oseltamivir |
| Q35310313 | In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1. |
| Q30226417 | Infectious respiratory disease outbreaks and pregnancy: occupational health and safety concerns of Canadian nurses |
| Q35645982 | Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008. |
| Q30384118 | Influenza and its treatment during pregnancy: A review. |
| Q37103929 | Influenza and respiratory syncytial virus in the elderly |
| Q30398099 | Influenza antivirals currently in late-phase clinical trial |
| Q37542274 | Influenza genome analysis using pyrosequencing method: current applications for a moving target |
| Q30423910 | Influenza in pregnancy |
| Q28282405 | Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance |
| Q28476585 | Influenza pandemic waves under various mitigation strategies with 2009 H1N1 as a case study |
| Q64950730 | Influenza viruses - antiviral therapy and resistance. |
| Q64065291 | Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil |
| Q36432764 | Insight into alternative approaches for control of avian influenza in poultry, with emphasis on highly pathogenic H5N1 |
| Q30385163 | Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu 'ado' from Japan. |
| Q30229309 | Issues relevant to the adoption and modification of hospital infection-control recommendations for avian influenza (H5N1 infection) in developing countries |
| Q30361125 | Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. |
| Q30402747 | Maternal deaths associated with H1N1 influenza virus infection in Turkey: a whole-of-population report |
| Q30373734 | Meeting report: risk assessment of tamiflu use under pandemic conditions. |
| Q30388975 | Methods for molecular surveillance of influenza |
| Q30373057 | Modeling the effects of drug resistant influenza virus in a pandemic |
| Q37105434 | Modeling the global transmission of antiviral-resistant influenza viruses |
| Q99207893 | Morin Hydrate Inhibits Influenza Virus entry into Host Cells and Has Anti-inflammatory Effect in Influenza-infected Mice |
| Q30356532 | Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. |
| Q30372421 | Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses |
| Q30228322 | Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children |
| Q30364619 | Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. |
| Q24197463 | Neuraminidase inhibitors for preventing and treating influenza in adults and children |
| Q24203905 | Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children |
| Q34986168 | Novel Influenza A (H1N1) Viral Infection in Late Pregnancy: Report of a Case |
| Q38886571 | Novel daidzein analogs and their in vitro anti-influenza activities |
| Q36171127 | Ode to oseltamivir and amantadine? |
| Q38652336 | Oseltamivir for influenza infection in children: risks and benefits |
| Q56785849 | Oseltamivir for treatment and prophylaxis of influenza infection |
| Q30386487 | Oseltamivir in human avian influenza infection. |
| Q30386485 | Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. |
| Q30394541 | Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. |
| Q30409023 | Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience |
| Q37087961 | Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung |
| Q37164761 | Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season |
| Q28474960 | Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets |
| Q30383709 | Pandemic influenza A (H1N1) 2009: the experience of the first six months. |
| Q30414197 | Pandemic influenza A(H1N1) 2009 virus in pregnancy |
| Q43103192 | Pandemic influenza and pregnant women |
| Q51934178 | Pandemic influenza and pregnant women: summary of a meeting of experts. |
| Q24628578 | Pandemic influenza threat and preparedness |
| Q30150801 | Pandemic influenza: are we ready? |
| Q30420391 | Pandemism of swine flu and its prospective drug therapy |
| Q40748977 | Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. |
| Q30357189 | Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. |
| Q48047617 | Plasmid-encoded biosynthetic genes alleviate metabolic disadvantages while increasing glucose conversion to shikimate in an engineered Escherichia coli strain |
| Q46558714 | Population pharmacokinetics of oseltamivir when coadministered with probenecid |
| Q28472381 | Population-wide emergence of antiviral resistance during pandemic influenza |
| Q30353815 | Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. |
| Q30383105 | Post-exposure prophylaxis during pandemic outbreaks |
| Q37323396 | Potential microbial origins of schizophrenia and their treatments |
| Q30352052 | Preparing for pandemic influenza: should hospitals stockpile oseltamivir? |
| Q30417369 | Progress in structure-based drug design against influenza A virus |
| Q30407650 | Prospects for controlling future pandemics of influenza |
| Q35574565 | Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada |
| Q58695383 | Rapid and simple detection of Tamiflu-resistant influenza virus: Development of oseltamivir derivative-based lateral flow biosensor for point-of-care (POC) diagnostics |
| Q35023358 | Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases |
| Q33869689 | Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009. |
| Q22305941 | Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors |
| Q27027408 | Safety and efficacy of peramivir for influenza treatment |
| Q37247004 | Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women |
| Q30382632 | Seasonal, avian, and novel H1N1 influenza: prevention and treatment modalities. |
| Q38907869 | Selectivity Improvement for Spectrofluorimetric Determination of Oseltamivir Phosphate in Human Plasma and in the Presence of Its Degradation Product |
| Q57726187 | Sensitivity of H5N1 influenza viruses to oseltamivir: an update |
| Q36691179 | Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal |
| Q91908893 | Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES) |
| Q30400232 | Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks |
| Q27663966 | Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses |
| Q43258764 | Structural basis for oseltamivir resistance of influenza viruses |
| Q24656213 | Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion |
| Q35099847 | Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden |
| Q36870919 | Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. |
| Q30376004 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| Q37689728 | Swine flu and pregnancy |
| Q90427288 | Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice |
| Q38047645 | Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection |
| Q36775625 | The Effect of Oseltamivir on the Disease Progression of Lethal Influenza A Virus Infection: Plasma Cytokine and miRNA Responses in a Mouse Model |
| Q35055899 | The fight against the influenza A virus H1N1: synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors. |
| Q36699830 | The metabolism and transplacental transfer of oseltamivir in the ex vivo human model |
| Q37696588 | The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome |
| Q30364977 | The role of oseltamivir in the treatment and prevention of influenza in children. |
| Q30356303 | The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. |
| Q36790658 | The threat of avian influenza A (H5N1). Part III: Antiviral therapy. |
| Q36171626 | Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation |
| Q58239529 | Transformation of D-Serine to Highly Functionalized Cyclohexenecarboxylates in Study of Oseltamivir Synthesis |
| Q30415228 | Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic |
| Q38838772 | Vaccination Is More Effective Than Prophylactic Oseltamivir in Preventing CNS Invasion by H5N1 Virus via the Olfactory Nerve |
| Q39766159 | Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza |
| Q30367126 | What the paediatrician needs to know when pandemic influenza arrives in clinical practice. |
| Q30379353 | Zanamivir-resistant influenza viruses with a novel neuraminidase mutation |